FEEDS
European Survey Highlights the Risk to Patients Caused by Inconsistency in Hypertension Management
Munich (ots/PRNewswire) - For distribution to the consumer and medical media across Europe (excluding the UK) - Findings From the Supporting Hypertension Awareness and Research Europe-wide (SHARE) Survey Suggest the Need to Implement a Consistent ... weiter zur Pressemitteilung von Daiichi Sankyo
Global Phase III Trial With Selective c-MET Inhibitor Tivantinib (ARQ 197) Starts Enrolling Patients in Europe
Munich (ots/PRNewswire) - Daiichi Sankyo announced today that it has begun enrolling patients in Europe into a large, multinational phase III trial of tivantinib (ARQ 197). Tivantinib is an investigational small molecule inhibitor of the c-MET ... weiter zur Pressemitteilung von Daiichi Sankyo
Daiichi Sankyo and ArQule Enroll First Non-Small Cell Lung Cancer Patient Into Global Phase III Trial for ARQ 197
Tokyo and Woburn, Massachusetts (ots/PRNewswire) - Daiichi Sankyo Company, Limited (TSE 4568) and ArQule, Inc. today announced that the first patient has been enrolled in the phase III trial of ARQ 197, an investigational selective inhibitor of the ... weiter zur Pressemitteilung von Daiichi Sankyo
Daiichi Sankyo Announces First European Approval for Sevikar HCT(R), a New Three-in-one Combination Product for the Treatment of High Blood Pressure*
Munich (ots/PRNewswire) - Daiichi Sankyo Europe announced today that Sevikar HCT(R) is now approved in Germany, the first market to launch this new once-daily three-in-one combination product for the treatment of high blood pressure (BP). This new ... weiter zur Pressemitteilung von Daiichi Sankyo
ArQule and Daiichi Sankyo Expand Drug Discovery Collaboration in Oncology
Woburn, Massachusetts (ots/PRNewswire) - ArQule, Inc. and Daiichi Sankyo Co., Ltd. (TSE 4568) today announced the expansion of their research, development and license agreement for the discovery of novel kinase inhibitors in the field of oncology. ... weiter zur Pressemitteilung von Daiichi Sankyo
Patients with Hypertension at Risk Due to Physician Inertia
Oslo, June 21, 2010 (ots/PRNewswire) - Data announced for the first time at ESH suggest that patients with hypertension are at increased cardiovascular risk due to clinician inertia, because physicians are failing to treat targets set by accepted ... weiter zur Pressemitteilung von Daiichi Sankyo
Daiichi Sankyo Submits First New Drug Application for Oral Factor Xa Inhibitor, Edoxaban
Tokyo, April 6, 2010 (ots/PRNewswire) - Daiichi Sankyo Company, Limited announced today that it has submitted a New Drug Application to the Ministry of Health, Labor and Welfare in Japan seeking approval of the anticoagulant, edoxaban, for the ... weiter zur Pressemitteilung von Daiichi Sankyo
HOKUSAI VTE - Largest Single Phase III Trial for the Treatment and Prevention of Recurrent VTE Started in Europe
Nuremberg, Germany, February 26, 2010 (ots/PRNewswire) - Edoxaban, a direct oral factor Xa inhibitor, is now being investigated in a second large-scale pivotal phase III trial, HOKUSAI (pronounced hoek-sigh) VTE. This phase III trial is evaluating ... weiter zur Pressemitteilung von Daiichi Sankyo
